Therefore, monitoring SLC3A2 expression levels in GBM patients undergoing paclitaxel treatment could help identify those who may be at a higher risk for drug resistance and tumor recurrence, and targeting SLC3A2 in combination with paclitaxel treatment might be a promising strategy for cancer therapy. This evidence concerns the gene SLC3A2 and neoplasm.